Introduction
GLP-1 agonists, originally used to manage diabetes, have gained popularity as a potential game-changer for weight loss. But how much do people in the UK really know about these medications? We carried out a study with Imperial College London, surveying 1,297 adults across the country to shed light on their knowledge, experiences, and attitudes.
Awareness of GLP-1 medications
Awareness of GLP-1 medications is relatively high, with nearly 8 in 10 people reporting they’ve heard of them. Women appear particularly engaged with this trend, often learning about GLP-1s through social media platforms like Instagram and TikTok, while men are less likely to encounter such content. However, awareness doesn’t necessarily equate to understanding. A considerable portion of respondents confessed limited knowledge of how these medications work. While 16% rated their understanding as excellent, 11% said it was very poor.
Safety concerns also play a significant role in shaping public opinion. Potential risks such as pancreatitis were identified as the leading worry, with three-quarters of respondents citing it as a concern.
Trusted information sources
When seeking information about GLP-1 medications, most people trust their healthcare providers above all else. Doctors and medical professionals were the preferred sources of advice for 71% of respondents, while reputable medical websites came in a close second. Social media and online influencers, although commonly used to spark initial curiosity, were not considered reliable when compared to expert recommendations.
The Long Journey to Weight Loss
For those currently using GLP-1 medications, weight loss has often been a long and complex journey. Many reported trying an average of three different methods to lose weight, with their efforts often spanning over a decade. Interestingly, these individuals were also more likely to report satisfaction with the medications; an impressive 91% said they would recommend GLP-1s to friends who are struggling with weight management.
Cost, however, remains a significant barrier. While nearly half of all respondents said they would consider using GLP-1 medications if they were free, the out-of-pocket expense of such treatments limits access for many.
Motivations and concerns
Improving health is the main driver for weight loss among respondents. Over 80% cited better overall health as their top motivation, followed by a desire to feel better emotionally, stay active, and improve energy levels and sleep quality. Many are also seeking weight loss to better manage specific health conditions.
Despite these motivators, barriers persist. Nearly 67% of respondents said consistency is the biggest challenge to weight loss, and more than half struggle with staying motivated. Time constraints also play a significant role, particularly for women, who were more likely than men to cite a lack of time as an obstacle.
Concerns about GLP-1 medications are also prominent. Many worry about the safety and side effects of these drugs, with 67% expressing concerns about potential risks and 65% fearing side effects. Additionally, there is a broad hesitancy about long-term results, with 65% anxious about regaining weight once they stop taking the medication. For many, the cost of GLP-1s further complicates their decision to use these treatments.
For individuals already using GLP-1 medications, attitudes are far more positive. These users are nearly seven times more likely to disagree with statements suggesting that the risks outweigh the benefits. They are also seven times more confident that enough evidence supports the safety of these treatments.
Conclusion
This survey highlights a nuanced picture of public perceptions surrounding GLP-1 medications in the UK. Current and past users of GLP-1 medications generally see them as safe and effective and often support making them more widely available to everyone, emphasising fair access for all. Interestingly, many people who haven’t used these medications are more skeptical, especially about their safety and how well they work. This shows that better public education is needed to address these concerns and provide clear, accurate information.